エストロゲン受容体アルファを分解する分子粘着剤としてブファリンを識別するための人工知能の活用
Shilong Jiang1,2, Keyi Liu3, Ting Jiang4
1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Nature communications
|August 22, 2025
まとめ
ブファリンは天然の化合物で,エストロゲン受容体アルファ (ERα) を分解する分子接着剤として作用する. このメカニズムは乳がんにおけるタモキシフェン耐性を逆転させ,新たな治療戦略を提供している.
科学分野:
- 薬理学について
- 分子生物学
- 薬物の発見
背景:
- 標的の特定は,天然製品から新しい抗癌薬の開発に不可欠です.
- ブファリンは抗がん性がありますが,その分子メカニズムは解明する必要があります.
研究 の 目的:
- ブファリンの分子標的と作用機構を特定する.
- 乳がんにおける内分泌抵抗の克服におけるBufalinの可能性を評価する.
主な方法:
- AI,分子ドッキング,分子ダイナミクスシミュレーションを含む統合マルチ予測戦略.
- 生物物理的検証試験 (SPR,バイオチン・プルダウン,熱変化)
- タモキシフェン耐性のインビトロ,インビボ,患者由来器官モデル.
主要な成果:
- ブファリンはエストロゲン受容体アルファ (ERα) に直接結合する.
- ブファリンは分子接着剤として機能し,STUB1媒介によるERα分解を促進する.
- ブファリンは,臨床前モデルと患者からのオーガノイドでタモキシフェン耐性を逆転させる.
結論:
- バファリンの分子接着メカニズムは,ERαの分解を標的とし,タモキシフェン耐性を克服するための新しい戦略を提供します.
- ブファリンは,内分泌抵抗性乳がんに対する有意な治療の可能性を示しています.
関連する概念動画
Transducer Mechanism: Nuclear Receptors
6.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.4K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Sedatives and Hypnotics Drugs: Miscellaneous Agents
939
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
939
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
682
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
682
Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K


